Drugs / anti-CEA 2nd generation designer T cells
anti-CEA 2nd generation designer T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01373047 | Jun 2011 → Jul 2013 | liver cancer | Roger Williams Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CEA 2nd generation designer T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01373047 ↗ |
| Action | Deplete | “so that they can attack and kill tumor cells” NCT01373047 ↗ |
| Modality | Cell therapy | “gene-modified T cells” NCT01373047 ↗ |
| Route | Other | “given via the hepatic artery using a percutaneous approach” NCT01373047 ↗ |